Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Original article

Vol. 144 No. 1314 (2014)

Observed costs and health care use of children in a prospective cohort study on community-acquired pneumonia in Geneva, Switzerland

  • Kristina Keitel
  • Gabriel Alcoba
  • Laurence Lacroix
  • Sergio Manzano
  • Annick Galetto-Lacour
  • Alain Gervaix
DOI
https://doi.org/10.4414/smw.2014.13925
Cite this as:
Swiss Med Wkly. 2014;144:w13925
Published
23.03.2014

Summary

QUESTIONS UNDER STUDY: Despite various efforts to estimate cost-effectiveness of pneumococcal conjugate vaccines, only scarce information on the cost burden of paediatric community acquired pneumonia (CAP) exists. The objective of this study was to prospectively calculate direct and indirect costs associated with treatment of CAP from a society perspective in children between 2 months and 16 years of age seeking care at a tertiary hospital in Geneva, Switzerland between December 2008 and May 2010.

METHODS: This cost of illness study population comprised children aged from 2 months to 16 years of age seeking care for CAP at the University Children’s Hospital Geneva from January 2008 through May 2010 (a subset of patients taken from a larger multicentre prospective cohort). Hospital-associated costs for episodes of pneumonia were computed according to the REKOLE® system. Non-hospital costs were estimated by parental interviews at baseline and follow-up on day 14.

RESULTS: The overall cost for one episode of CAP was 11’258 CHF; 23’872 CHF for inpatient treatment and 1009 CHF for outpatient treatment. Severe pneumonia cases per World Health Organisation (WHO) definition used significantly more hospital resources than non-severe cases: 21’842 CHF versus 3479 CHF (p <0.0001).

CONCLUSION: Childhood CAP results in a significant medical cost burden that may have been underestimated in previous cost-effectiveness analyses of pneumococcal vaccine strategies.

References

  1. Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008;86(5):408–16. PMCID: 2647437.
  2. British Thoracic Society Guidelines for the Management of Community Acquired Pneumonia in Childhood. Thorax. 2002;57 Suppl 1:i1–24. PMCID: 1765993.
  3. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19(3):187–95.
  4. Senstad AC, Suren P, Brauteset L, Eriksson JR, Hoiby EA, Wathne KO. Community-acquired pneumonia (CAP) in children in Oslo, Norway. Acta Paediatr. 2009;98(2):332–6.
  5. Don M, Fasoli L, Paldanius M, Vainionpaa R, Kleemola M, Raty R, et al. Aetiology of community-acquired pneumonia: serological results of a paediatric survey. Scand J Infect Dis. 2005;37(11–12):806–12.
  6. Juven T, Mertsola J, Waris M, Leinonen M, Meurman O, Roivainen M, et al. Etiology of community-acquired pneumonia in 254 hospitalized children. Pediatr Infect Dis J. 2000;19(4):293–8.
  7. Michelow IC, Olsen K, Lozano J, Rollins NK, Duffy LB, Ziegler T, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004;113(4):701–7.
  8. Cevey-Macherel M, Galetto-Lacour A, Gervaix A, Siegrist CA, Bille J, Bescher-Ninet B, et al. Etiology of community-acquired pneumonia in hospitalized children based on WHO clinical guidelines. Eur J Pediatr. 2009;168(12):1429–36.
  9. Invasive pneumococcal disease in young children before licensure of 13–valent pneumococcal conjugate vaccine – United States, 2007. MMWR Morb Mortal Wkly Rep. 59(9):253–7.
  10. De Graeve D, Beutels P. Economic aspects of pneumococcal pneumonia: a review of the literature. Pharmacoeconomics. 2004;22(11):719–40.
  11. Jacob C, Mittendorf T, Graf von der Schulenburg JM. [Costs of illness and health-related quality of life for community-acquired pneumonia – a systematic review]. Pneumologie. 2011;65(8):498–502.
  12. Hospitals FoS. REKOLE® – comptabilité de gestion à l’hôpital. 2008 [updated 2008 09/16/2011; cited]; 2008: Available from: http://www.hplus.ch/fr/gestion/comptabilite_des_hopitaux/rekoleR_le_livre/?type=orig.
  13. Wages and income from employment. Lake Geneva Region. Swiss Federal Statistical Office. 2010. Available from: http://www.bfs.admin.ch/bfs/portal/en/index/themen/03/04/blank/data/01/06_02.html.
  14. Hahn, G. J. and Meeker, W. Q. (1991), Statistical Intervals: A Guide for Practitioners, New York: John Wiley & Sons.
  15. Pappas DE, Hendley JO. The common cold and decongestant therapy. Pediatr Rev. 2011;32(2):47–54; quiz 5.
  16. Geneva canton regional demographic data. Swiss Federal Statistical Office. 20009. Available from: http://www.bfs.admin.ch/bfs/portal/en/index/regionen/regionalportraets/genf/blank/kennzahlen.html.
  17. Ess SM, Schaad UB, Gervaix A, Pinosch S, Szucs TD. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine. 2003;21(23):3273–81.
  18. Black S, Lieu TA, Ray GT, Capra A, Shinefield HR. Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente. Vaccine. 2000;19 Suppl 1:S83–6.
  19. Claes C, Graf von der Schulenburg JM. Cost effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany. Pharmacoeconomics. 2003;21(8):587–600.
  20. Kalies K, Hermann M, Schmitt HJ, Kries RV. Pravention invasiver Pneumokokken infektionen im Kindersalter. Welche Impfstrategie ist zu empfehlen. Kinderaerztliche Praxis. 2001;72:90–8.
  21. Data on Gender Equality. Employment models in couple households. Swiss Federal Statistical Office 2010. Available at: http://www.bfs.admin.ch/bfs/portal/en/index/themen/20/05/blank/key/Vereinbarkeit/04.html.
  22. Lieu TA, Ray GT, Black SB, Butler JC, Klein JO, Breiman RF, et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA. 2000;283(11):1460–8.
  23. Atkinson M, Lakhanpaul M, Smyth A, Vyas H, Weston V, Sithole J, et al. Comparison of oral amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children (PIVOT trial): a multicentre pragmatic randomised controlled equivalence trial. Thorax. 2007;62(12):1102–6. PMCID: 2094276.
  24. Tsarouhas N, Shaw KN, Hodinka RL, Bell LM. Effectiveness of intramuscular penicillin versus oral amoxicillin in the early treatment of outpatient pediatric pneumonia. Pediatr Emerg Care. 1998;14(5):338–41.
  25. Hazir T, Fox LM, Nisar YB, Fox MP, Ashraf YP, MacLeod WB, et al. Ambulatory short-course high-dose oral amoxicillin for treatment of severe pneumonia in children: a randomised equivalency trial. Lancet. 2008;371(9606):49–56.
  26. Li ST, Tancredi DJ. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Pediatrics. 2010;125(1):26–33.
  27. Byington CL, Spencer LY, Johnson TA, Pavia AT, Allen D, Mason EO, et al. An epidemiological investigation of a sustained high rate of pediatric parapneumonic empyema: risk factors and microbiological associations. Clin Infect Dis. 2002;34(4):434–40.
  28. Resti M, Moriondo M, Cortimiglia M, Indolfi G, Canessa C, Becciolini L, et al. Community-acquired bacteremic pneumococcal pneumonia in children: diagnosis and serotyping by real-time polymerase chain reaction using blood samples. Clin Infect Dis.51(9):1042–9.
  29. Smyth AR, Barbato A, Beydon N, Bisgaard H, de Boeck K, Brand P, et al. Respiratory medicines for children: current evidence, unlicensed use and research priorities. Eur Respir J.35(2):247–65.

Most read articles by the same author(s)